Intuitive Surgical (NASDAQ:ISRG) Price Target Increased to $500.00 by Analysts at Mizuho

Intuitive Surgical (NASDAQ:ISRG) had its price objective lifted by equities researchers at Mizuho from $440.00 to $500.00 in a research note issued on Thursday. Mizuho’s target price suggests a potential upside of 5.36% from the company’s current price.

Other analysts also recently issued research reports about the company. Morgan Stanley upped their price target on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Evercore ISI upped their price target on shares of Intuitive Surgical from $410.00 to $475.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. BTIG Research upped their price objective on Intuitive Surgical from $494.00 to $518.00 and gave the stock a “buy” rating in a report on Monday. Robert W. Baird upped their target price on Intuitive Surgical from $503.00 to $565.00 in a research note on Thursday. Finally, Truist Financial lifted their price objective on shares of Intuitive Surgical from $520.00 to $570.00 and gave the company a “buy” rating in a report on Monday. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $484.15.

Intuitive Surgical Stock Performance

ISRG stock traded down $2.04 during mid-day trading on Thursday, hitting $474.55. The company had a trading volume of 651,718 shares, compared to its average volume of 1,459,238. The firm has a market cap of $168.32 billion, a PE ratio of 85.71, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. Intuitive Surgical has a 12 month low of $254.85 and a 12 month high of $496.48. The stock’s fifty day moving average price is $482.49 and its two-hundred day moving average price is $436.65.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter last year, the company posted $1.18 EPS. The business’s quarterly revenue was up 14.5% on a year-over-year basis. Equities analysts anticipate that Intuitive Surgical will post 5.22 earnings per share for the current year.

Insider Activity

In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the completion of the sale, the senior vice president now owns 3,001 shares in the company, valued at approximately $1,461,006.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Robert Desantis sold 188 shares of Intuitive Surgical stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $482.21, for a total transaction of $90,655.48. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,655,048.26. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now owns 3,001 shares in the company, valued at $1,461,006.84. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 53,120 shares of company stock worth $25,528,753. Company insiders own 0.90% of the company’s stock.

Institutional Trading of Intuitive Surgical

A number of hedge funds have recently added to or reduced their stakes in the stock. Capital Research Global Investors acquired a new stake in shares of Intuitive Surgical during the 1st quarter worth approximately $374,390,000. Vanguard Group Inc. boosted its holdings in Intuitive Surgical by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after buying an additional 493,126 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of Intuitive Surgical by 51.2% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock worth $356,524,000 after buying an additional 302,382 shares in the last quarter. Strategic Financial Concepts LLC boosted its stake in Intuitive Surgical by 40,221.4% during the second quarter. Strategic Financial Concepts LLC now owns 266,121 shares of the medical equipment provider’s stock valued at $1,184,000 after buying an additional 265,461 shares during the period. Finally, GQG Partners LLC bought a new position in shares of Intuitive Surgical in the 1st quarter worth $99,523,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.